ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) reported Q3 EPS of ($0.52), $0.06 worse than the analyst estimate of ($0.46). Revenue for the quarter came in at $32.5 million versus the consensus estimate of $28.56 million.

For earnings history and earnings-related data on ARS Pharmaceuticals, Inc. (SPRY) click here.